Neutrophil (PMN)3 activation plays a central role in diverse responses such as host defense, inflammation, and reperfusion injury (1). In response to inflammatory stimuli, PMN target reactive oxygen species and granule enzymes to phagolysosomes for microbial killing or digestion of foreign materials (2). Anomalous release of these potentially toxic agents often occurs, amplifying inflammation and leading to tissue injury, events that are implicated in a wide range of human diseases (3). To prevent an overexuberant inflammatory response and limit damage to the host, PMN programs are tightly regulated with select bioactive lipids serving as endogenous anti-inflammatory signals (4).It is now well appreciated that several enzymes of lipid metabolism also serve as signaling modules with their products acting as bioeffectors (5, 6). Polyisoprenyl phosphates, specifically the mevalonate-derived product presqualene diphosphate (PSDP), carry biological activity as an intracellular down-regulatory signal in human PMNs (7). PSDP directly inhibits phospholipase D (PLD) and leukocyte superoxide anion generation in vitro and in vivo (8,9). Recently, the hyperimmunoglobulinemia D and periodic fever syndrome were identified as a systemic inflammatory illness stemming from partial deletion of mevalonate kinase and subsequently decreased isoprenoid production (10, 11). Together, these observations indicate that in addition to their roles as structural elements in cholesterol biosynthesis, mevalonate-derived products can also display properties of lipid mediators in inflammation.Cell activation by receptor-mediated agonists leads to rapid and transient polyisoprenyl phosphate remodeling (7,8). PSDP is present in freshly isolated human PMN. When cells are activated, PSDP shifts from perinuclear to granule and microsomal subcellular domains, and within seconds is converted to its monophosphate form, presqualene monophosphate (PSMP) (7, 12). As an inhibitor of PLD and reactive oxygen species generation, PSMP is over 100-fold less potent than PSDP (8). These findings suggest the presence of a regulated diphosphate phosphatase. Here, we report the identification of the first PSDP phosphatase in human PMN and characterize its biochemical properties.
EXPERIMENTAL PROCEDURESMaterials-Phosphatidic acid (PA, C10:0) and diacylglycerol pyrophosphate (DGPP, C18:1) were purchased from Avanti Polar Lipids (Alabaster, AL) and FDP from Sigma. Leukotriene B 4 was from Cayman Chemical (Ann Arbor, MI). Plasmids encoding the LPPRP2 gene were purchased from Origene (Rockville, MD). Recombinant human phosphatidic acid phosphohydrolase 2a (PAP2a), PAP2b, and PAP2c were generated as described in Ref. 13. [ 14 C]FDP (55 mCi/mmol, 50 Ci/ml) was from American Radiolabeled Chemicals (St. Louis, MO). PSDP was isolated from healthy human PMNs as described (7).Purification of PSDP Phosphatase Activity from PMN-Human PMN were isolated from whole blood as described (7), suspended (10 7 PMN/ ml) in Hanks' balanced salt solution with 1.6 mM CaCl 2 , warmed (5 min,...